AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11195606 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (50-100 mg twice daily)
Number of subjects: 34
Study 11195606 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (60-120 mg three times daily)
Number of subjects: 34
Study 9421122 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy with ranitidine 300 mg b.i.d and clarithromycin 750 mg b.i.d, plus placebo (Group A)
Number of subjects: 105
Study 9421122 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy with ranitidine 300 mg b.i.d and clarithromycin 750 mg b.i.d, plus lymecycline 300 mg b.i.d (Group B)
Number of subjects: 105
Study 8050697 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 24
Study 8050697 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth 240 mg
Number of subjects: 24
Study 8050697 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg + Bismuth 240 mg
Number of subjects: 24
Study 3430154 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous passive motion (CPM)
Number of subjects: 62
Study 3430154 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 62
Study 30547732 — intervention group
Group type: EXPERIMENTAL
Intervention: PRETmax (5 stages at RPE 11, 13, 15, 17, 20)
Number of subjects: 10
Study 30547732 — intervention group
Group type: COMPARATOR
Intervention: RAMP (0‐40 W + 5‐10 W · min‐1)
Number of subjects: 10
Study 30547732 — intervention group
Group type: EXPERIMENTAL
Intervention: PRETmax
Number of subjects: 10
Study 27392728 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping and Promoting Strength program (CAPS)
Number of subjects: 136
Study 27392728 — intervention group
Group type: COMPARATOR
Intervention: Information Monitoring (IM)
Number of subjects: 136
Study 26364530 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program based on INR monitoring
Number of subjects: 33
Study 26364530 — intervention group
Group type: COMPARATOR
Intervention: General care (control group)
Number of subjects: 33
Study 23547765 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education program
Number of subjects: 0
Study 23547765 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 21422854 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole and erythromycin
Number of subjects: 269
Study 19056608 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemic clamp (2.8 mmol/l)
Number of subjects: 20
Study 18273404 — intervention group
Group type: EXPERIMENTAL
Intervention: Home testing for chlamydia and gonorrhea
Number of subjects: 0
Study 18273404 — intervention group
Group type: COMPARATOR
Intervention: Clinic testing for chlamydia and gonorrhea
Number of subjects: 0
Study 18273404 — intervention group
Group type: EXPERIMENTAL
Intervention: Home testing
Number of subjects: 0
Study 15073266 — intervention group
Group type: EXPERIMENTAL
Intervention: (11)C-DASB
Number of subjects: 6
Study 15073266 — intervention group
Group type: COMPARATOR
Intervention: (11)C-McN 5652
Number of subjects: 6
Study 15073266 — intervention group
Group type: EXPERIMENTAL
Intervention: Both (11)C-DASB and (11)C-McN 5652
Number of subjects: 6
Study 11437980 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric liquid meal with paracetamol administered orally without nasogastric tube
Number of subjects: 9
Study 11437980 — intervention group
Group type: COMPARATOR
Intervention: Caloric liquid meal with paracetamol administered orally with nasogastric tube
Number of subjects: 9
Study 11437980 — intervention group
Group type: COMPARATOR
Intervention: Gastric tube intervention
Number of subjects: 9
Study 9709138 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake group
Number of subjects: 60
Study 9709138 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthetised group
Number of subjects: 60
Study 9709138 — intervention group
Group type: EXPERIMENTAL
Intervention: Mask group
Number of subjects: 60
Study 9709138 — intervention group
Group type: COMPARATOR
Intervention: Control (pooled groups)
Number of subjects: 60
Study 8034208 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy (3000 cGy)
Number of subjects: 60
Study 8034208 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 60
Study 2498089 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 10 micrograms kg‐1 1 min prior to induction of anaesthesia
Number of subjects: 21
Study 2498089 — intervention group
Group type: COMPARATOR
Intervention: Control group (16 patients)
Number of subjects: 21
Study 4413081 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone, 3 mg/kg per day for 10 days
Number of subjects: 16
Study 4413081 — intervention group
Group type: COMPARATOR
Intervention: Sodium salicylate, 100 mg/kg per day for 10 days
Number of subjects: 16
Study 31765110 — intervention group
Group type: EXPERIMENTAL
Intervention: lisdexamfetamine 20 mg on Day 1, then 20 mg/d (Days 4-8), 50 mg/d (Days 9-13), 70 mg/d (Days 14-18)
Number of subjects: 34
Study 31765110 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 34
Study 30723954 — intervention group
Group type: EXPERIMENTAL
Intervention: Six web-based learning modules followed by two face-to-face group sessions
Number of subjects: 103
Study 30723954 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 103
Study 29972903 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotomy group
Number of subjects: 20
Study 29972903 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 26410620 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 150 mg/m² on days 1, 8, and 15 every 4 weeks
Number of subjects: 529
Study 26410620 — intervention group
Group type: COMPARATOR
Intervention: dacarbazine 1000 mg/m² every 3 weeks
Number of subjects: 529
Study 23465055 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine 4 mg once daily for the first 4 weeks, with an option to increase to 8 mg once daily for the remaining 8 weeks
Number of subjects: 322
Study 23465055 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine treatment
Number of subjects: 322
Study 21430035 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed intermittent bolus 10 mL every 60 minutes (10/60)
Number of subjects: 190
Study 21430035 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed intermittent bolus 5 mL every 30 minutes (5/30)
Number of subjects: 190
Study 21430035 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed intermittent bolus 2.5 mL every 15 minutes (2.5/15)
Number of subjects: 190
Study 19301089 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (35 mg/week), calcium (1,000 mg/day), and vitamin D (400 IU/day) for 12 months
Number of subjects: 61
Study 19301089 — intervention group
Group type: COMPARATOR
Intervention: Calcium (1,000 mg/day) and vitamin D (400 IU/day)
Number of subjects: 61
Study 17049060 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF with 50% dose reduction of CsA
Number of subjects: 103
Study 17049060 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintenance CsA dose)
Number of subjects: 103
Study 12775136 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral montelukast
Number of subjects: 104
Study 12775136 — intervention group
Group type: COMPARATOR
Intervention: Inhaled fluticasone propionate
Number of subjects: 104
Study 12775136 — intervention group
Group type: EXPERIMENTAL
Intervention: Both montelukast and fluticasone
Number of subjects: 104
Study 10848652 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 5 mg
Number of subjects: 38
Study 10848652 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg
Number of subjects: 38
Study 10848652 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 38
Study 10848652 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 40 mg
Number of subjects: 38
Study 10848652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 9322642 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet-pivoxil (2 gm single oral dose)
Number of subjects: 320
Study 9322642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study 8418401 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy plus optimal medical treatment (aspirin) (surgical group; n=211)
Number of subjects: 444
Study 8418401 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical treatment alone (medical group; n=233)
Number of subjects: 444
Study 3914180 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B-6 100 mg daily
Number of subjects: 34
Study 3914180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 3914180 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B-6 100 mg daily and Placebo
Number of subjects: 34
Study 30187345 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg/day
Number of subjects: 396
Study 30187345 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg/day
Number of subjects: 396
Study 26931249 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold dissection method
Number of subjects: 96
Study 26931249 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar dissection tonsillectomy
Number of subjects: 96
Study 26931249 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser tonsillectomy
Number of subjects: 96
Study 23910233 — intervention group
Group type: EXPERIMENTAL
Intervention: One-third dose BCG
Number of subjects: 1316
Study 23910233 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose BCG
Number of subjects: 1316
Study 23910233 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 year of maintenance BCG
Number of subjects: 1316
Study 23910233 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 years of maintenance BCG
Number of subjects: 1316
Study 23910233 — intervention group
Group type: COMPARATOR
Intervention: Overall treatment arms
Number of subjects: 1316
Study 23910233 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical cystitis
Number of subjects: 1316
Study 23910233 — intervention group
Group type: EXPERIMENTAL
Intervention: General malaise
Number of subjects: 1316
Study 23910233 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment stoppage due to side effects
Number of subjects: 1316
Study 23910233 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 years of BCG
Number of subjects: 1316
Study 22089885 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung Volume Reduction Surgery (LVRS)
Number of subjects: 1086
Study 22089885 — intervention group
Group type: COMPARATOR
Intervention: Standard Multidisciplinary Medical Therapy (MT)
Number of subjects: 1086
Study 16120033 — intervention group
Group type: EXPERIMENTAL
Intervention: Softsense meter (MediSense Products)
Number of subjects: 52
Study 16120033 — intervention group
Group type: COMPARATOR
Intervention: Optium meter (MediSense Products)
Number of subjects: 52
Study 11535961 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants or counselling
Number of subjects: 0
Study 11535961 — intervention group
Group type: COMPARATOR
Intervention: Non-directive counselling, cognitive-behaviour therapy, or usual general practitioner care
Number of subjects: 0
Study 9845864 — intervention group
Group type: EXPERIMENTAL
Intervention: High-structure, behaviorally oriented (HSB) counseling
Number of subjects: 60
Study 9845864 — intervention group
Group type: COMPARATOR
Intervention: Low-structure, facilitative (LSF) counseling
Number of subjects: 60
Study 9845864 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HSB and LSF counseling
Number of subjects: 60
Study 7855658 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch
Number of subjects: 77
Study 7855658 — intervention group
Group type: COMPARATOR
Intervention: Organized smoking cessation program
Number of subjects: 77
Study 2520783 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminaria tent
Number of subjects: 519
Study 2520783 — intervention group
Group type: COMPARATOR
Intervention: Hegar dilators
Number of subjects: 519
Study 994315 — intervention group
Group type: EXPERIMENTAL
Intervention: fusaric acid calcium salt
Number of subjects: 5
Study 994315 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 5
Study 29475094 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulthiame
Number of subjects: 43
Study 29475094 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 43
Study 29475094 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 43
Study 29475094 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with recurrent seizures
Number of subjects: 43
Study 27994503 — intervention group
Group type: EXPERIMENTAL
Intervention: Far-Infrared Radiation (FIR) therapy applied for 40 minutes during each hemodialysis session, three times per week for six months.
Number of subjects: 108
Study 27994503 — intervention group
Group type: COMPARATOR
Intervention: Control group (no FIR therapy).
Number of subjects: 108
Study 24126498 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified gap-balancing technique
Number of subjects: 40
Study 24126498 — intervention group
Group type: COMPARATOR
Intervention: Conventional navigation-based TKA
Number of subjects: 40
Study 21689141 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy with amoxicillin, clarithromycin and lansoprazole twice daily for 2 weeks
Number of subjects: 204
Study 21689141 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy with amoxicillin and lansoprazole three times daily for 2 weeks
Number of subjects: 204
Study 21689141 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 204
Study 21689141 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy
Number of subjects: 204
Study 19887860 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-fed infants (BF)
Number of subjects: 74
Study 19887860 — intervention group
Group type: COMPARATOR
Intervention: Formula-fed infants (FF)
Number of subjects: 74
Study 18955665 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg daily
Number of subjects: 26512
Study 15901045 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated tablet formulation A (5 mg finasteride)
Number of subjects: 26
Study 15901045 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated tablet formulation B (5 mg finasteride)
Number of subjects: 26
Study 12682575 — intervention group
Group type: EXPERIMENTAL
Intervention: Snoezelen multisensory environment
Number of subjects: 26
Study 12682575 — intervention group
Group type: COMPARATOR
Intervention: Normal 'quiet room' setting
Number of subjects: 26
Study 10817796 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast 20 mg twice daily
Number of subjects: 0
Study 10817796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8856392 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT) in obese patients
Number of subjects: 19
Study 8856392 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglycemic‐hyperinsulinemic clamp in obese patients
Number of subjects: 19
Study 1641497 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive imipramine added to ongoing medication regimen of fluphenazine decanoate and benztropine
Number of subjects: 21
Study 1641497 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive imipramine
Number of subjects: 21
Study 6405480 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune serum globulin (ISG) administered to all subjects in group A (79% immunized)
Number of subjects: 100
Study 6405480 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune serum globulin (ISG) administered to 50% of subjects in group B (36% immunized)
Number of subjects: 100
Study 6405480 — intervention group
Group type: COMPARATOR
Intervention: Non-immunized control group (C)
Number of subjects: 100
Study 30840773 — intervention group
Group type: EXPERIMENTAL
Intervention: PVB19 DNA testing using quantitative PCR
Number of subjects: 1500
Study 28890353 — intervention group
Group type: EXPERIMENTAL
Intervention: Messages about arsenic, formaldehyde, lead, uranium, and ammonia
Number of subjects: 1148
Study 28890353 — intervention group
Group type: EXPERIMENTAL
Intervention: Messages containing information on toxic products, health effects, or both
Number of subjects: 1148
Study 28890353 — intervention group
Group type: EXPERIMENTAL
Intervention: Constituent-only messages referencing multiple constituents
Number of subjects: 1148
Study 26847969 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual CPAP
Number of subjects: 23
Study 26847969 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 23
Study 25256660 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg via subcutaneous injection into the abdomen
Number of subjects: 60
Study 25256660 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg via subcutaneous injection into the upper arm
Number of subjects: 60
Study 25256660 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg via subcutaneous injection into the thigh
Number of subjects: 60
Study 25256660 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg via subcutaneous injection (all sites)
Number of subjects: 60
Study 22429665 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural intervention lasting for 10 weeks
Number of subjects: 40
Study 22429665 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 40
Study 22429665 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural intervention
Number of subjects: 40
Study 20425572 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control in type 2 diabetic patients
Number of subjects: 0
Study 20425572 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight glycemic control in critically ill patients
Number of subjects: 0
Study 20425572 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control in type 1 diabetic patients
Number of subjects: 0
Study 20425572 — intervention group
Group type: COMPARATOR
Intervention: Tight glycemic control in critically ill patients (initial studies)
Number of subjects: 0
Study 20425572 — intervention group
Group type: COMPARATOR
Intervention: Tight glycemic control in critically ill patients (subsequent studies)
Number of subjects: 0
Study 17916813 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramedic practitioner service active
Number of subjects: 3018
Study 17916813 — intervention group
Group type: COMPARATOR
Intervention: Standard ambulance transfer and treatment
Number of subjects: 3018
Study 16108890 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil plus leucovorin
Number of subjects: 147
Study 16108890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 12143944 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal patch (n=149)
Number of subjects: 1291
Study 12143944 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nitrates (n=504)
Number of subjects: 1291
Study 12143944 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oral and transdermal nitrates (n=60)
Number of subjects: 1291
Study 12143944 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment (n=578)
Number of subjects: 1291
Study 9989541 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH combination diet
Number of subjects: 459
Study 9989541 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruits and vegetables diet
Number of subjects: 459
Study 9989541 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 459
Study 7476284 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin/glucose infusion at 0.025/2.0 U/kg.h and mg/kg.min
Number of subjects: 48
Study 7476284 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin/glucose infusion at 0.050/3.5 U/kg.h and mg/kg.min
Number of subjects: 48
Study 7476284 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin/glucose infusion at 0.100/6.0 U/kg.h and mg/kg.min
Number of subjects: 48
Study 7476284 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin/glucose infusion at 0.200/8.0 U/kg.h and mg/kg.min
Number of subjects: 48
Study 2179134 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime at a dosage of 2 x 3 g/day for ten days
Number of subjects: 135
Study 2179134 — intervention group
Group type: COMPARATOR
Intervention: Penicillin G at a dosage of 2 x 10 megaunits/day for ten days
Number of subjects: 135
Study 2179134 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 135
Study 2179134 — intervention group
Group type: COMPARATOR
Intervention: Penicillin G
Number of subjects: 135
Study 450561 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral safflower oil (1 gm/kg/day)
Number of subjects: 11
Study 450561 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of vitamin E (10 mg/kg/day) to safflower oil
Number of subjects: 11
Study 450561 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 11
Study 30692241 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher maternal DBP levels at delivery
Number of subjects: 189
Study 30692241 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher cord blood 25(OH)D levels
Number of subjects: 189
Study 28687375 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) of the resection cavity (within 30 days of surgery)
Number of subjects: 132
Study 28687375 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 132
Study 25565495 — intervention group
Group type: EXPERIMENTAL
Intervention: Social network intervention
Number of subjects: 626
Study 25565495 — intervention group
Group type: COMPARATOR
Intervention: Standard HIV/STD testing/counseling
Number of subjects: 626
Study 22451021 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-thermal, non-invasive pulsed electromagnetic field (PEMF) therapy
Number of subjects: 34
Study 22451021 — intervention group
Group type: COMPARATOR
Intervention: Sham cohort (placebo)
Number of subjects: 34
Study 20142306 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg dDAVP bolus (over 1 min)
Number of subjects: 12
Study 20142306 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 μg dDAVP incremental infusion (over 60 min)
Number of subjects: 12
Study 20142306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 19261236 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (40 mg/100 ml)
Number of subjects: 68